Business Wire22d
World’s First Drug Candidate developed by Organoid and AI Doses First Patient in Phase 1 Study for first Diffusive Gastric Cancer Targeted Therapy
This marks a significant milestone as SIGX1094 is the first pipeline drug discovered using AI and organoid disease model to enter clinical trials, and the first targeted therapy candidate to ...
News Medical2y
Essential growth factors (recombinant) for organoid cultures
Organoid technology has lately risen to prominence as a critical tool for both basic and biomedical research. Embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and primary ...
Medscape11d
Selective inhibition of CDK9 in triple negative breast cancer.
Growth of five distinct patient-derived organoid models was dose-dependently inhibited by CDDD11-8 (IC50 range: 272-771 nM), including three derived from MYC amplified, chemo-resistant TNBC ...